ORCHESTRATING A CURE FOR DYSFERLINOPATHY

The Jain Foundation is singularly focused on finding a cure for dysferlinopathy, also referred to as LGMD2B, LGMDR2, Miyoshi Myopathy 1

ORCHESTRATING
A CURE FOR
DYSFERLINOPATHY

The Jain Foundation is singularly focused on finding a cure for dysferlinopathy, also referred to as LGMD2B, LGMDR2, Miyoshi Myopathy 1

WHAT IS DYSFERLINOPATHY?

LGMD2B/LGMDR2/MIYOSHI MYOPATHY 1

The Jain Foundation is exploring all avenues from the laboratory bench to bedside in the quest of identifying treatments for dysferlinopathy. Our innovative approach supports groundbreaking research, development of resources, diagnostic and educational programs, pre-clinical testing of promising treatments, and the development of tools needed to run successful clinical trials, such as a disease specific registry and outcome measures.

Through the collaborative effort of the many people involved in this effort, Jain Foundation staff, researchers, clinicians, patients, caregivers, regulatory agencies, and industry, we are driving real change for those with dysferlinopathy.

ARE YOU INCLUDED IN THE DYSFERLIN REGISTRY?

The Jain Foundation curates a global registry of individuals who are genetically confirmed with dysferlinopathy, also referred to as LGMD2B, LGMDR2, Miyoshi Myopathy 1, which will help our community mobilize fast for clinical trials.

ARE YOU
INCLUDED IN THE
DYSFERLIN REGISTRY?

The Jain Foundation curates a global registry of individuals who are genetically confirmed with dysferlinopathy, also referred to as LGMD2B, LGMDR2, Miyoshi Myopathy 1, which will help our community mobilize fast for clinical trials.

Dysferlin Research Blog

Dysferlin Research Blog

A blog for researchers in the dysferlinopathy field with content about research protocols and tools, abstract deadlines for upcoming conferences, newly published research and pivotal scientific advances.

Dysferlin Research Blog

A blog for researchers in the dysferlinopathy field with content about research protocols and tools, abstract deadlines for upcoming conferences, newly published research and pivotal scientific advances.

MAKING AN IMPACT

FUNDING MISSION CRITICAL PROGRAMS

140+

We carefully select and monitor research projects, studies and other programs to advance our mission

INVESTING
IN THE CURE

$40+M

Over 40 million dollars invested in research, drug development and patient support and education

WORKING TOWARDS
THE FUTURE

COS

Our Clinical Outcome Study (COS) provides critical information for the successful design of clinical trials

PREPARING THE COMMUNITY FOR TRIALS

1,200+

We have identified over 1,200 genetically confirmed individuals with dysferlinopathy worldwide

MAKING AN IMPACT

FUNDING MISSION
CRITICAL PROGRAMS

140+

We carefully select and monitor research projects, studies and other programs to advance our mission

INVESTING
IN THE CURE

$40+M

Over 40 million dollars invested in research, drug development and patient support and education

WORKING TOWARDS
THE FUTURE

COS

Our Clinical Outcome Study (COS) provides critical information for the successful design of clinical trials

PREPARING THE COMMUNITY FOR TRIALS

1,100+

We have identified over 1,100 genetically confirmed individuals with dysferlinopathy worldwide

MAKING AN IMPACT

FUNDING MISSION CRITICAL PROGRAMS

140+

We carefully select and monitor research projects, studies and other programs to advance our mission

INVESTING
IN THE CURE

$40+M

Over 40 million dollars invested in research, drug development and patient support and education

WORKING TOWARDS
THE FUTURE

COS

Our Clinical Outcome Study (COS) provides critical information for the successful design of clinical trials

PREPARING THE COMMUNITY FOR TRIALS

1,100+

We have identified over 1,100 genetically confirmed individuals with dysferlinopathy worldwide